"The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development."
"Management remains committed to ensuring that SOHM achieves higher revenue growth in 2024 compared to previous years. This includes the revenues from our new ABBIE kits. Dr. David Aguilar, COO added."
"Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits. This is significant miles stone for the company and we are very happy to transition from Research and Development to commercialization of GLP ABBIE Technology Kits.
The current CRISPR/Cas9 kits business is expected to grow $ 17.4 billion by year 2032."